Casdin Capital, LLC Fulcrum Therapeutics, Inc. Transaction History

Casdin Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$7.28 - $30.97 $8.4 Million - $35.8 Million	-1,154,476 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$8.09 - $12.0 $701,403 - $1.04 Million	-86,700 Reduced 6.99%	1,154,476 $12.1 Million
Q4 2020 Feb 16, 2021	SELL	$7.84 - $13.4 $1.57 Million - $2.68 Million	-200,000 Reduced 13.88%	1,241,176 $14.5 Million
Q2 2020 Aug 14, 2020	BUY	$9.11 - $22.06 $2.11 Million - $5.12 Million	231,891 Added 19.18%	1,441,176 $26.4 Million
Q1 2020 May 15, 2020	SELL	$9.49 - $21.26 $284,700 - $637,800	-30,000 Reduced 2.42%	1,209,285 $14.4 Million
Q4 2019 Feb 14, 2020	BUY	$4.46 - $18.14 $1.76 Million - $7.17 Million	395,000 Added 46.79%	1,239,285 $20.6 Million
Q3 2019 Nov 12, 2019	BUY	$6.64 - $14.89 $5.61 Million - $12.6 Million	844,285 New	844,285 $5.27 Billion

150

52.2M

6.91M

1.9M

Ticker FULC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,038,900
Market Cap $158M
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...

Get notified when there are updates to the investment portfolio of Casdin Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Casdin Capital, LLC with notifications on news.